Consumers take the offensive against J&J for Tylenol recalls

A constant supply of bad news is jeopardizing the long-term sales of Tylenol and other Johnson & Johnson (NYSE: JNJ) products, says Motley Fool columnist Brian Orelli. "Contrary to the popular saying, there is such a thing as bad press and if you're getting it month after month, it's even worse." If J&J can't overcome the negative image quickly, he says, consumers will head to competing brand-name drugs or just grab generics. They also make take more direct action: Consumers are accusing the drugmaker of fraud and racketeering in a lawsuit stemming from the recent recall, and demanding cash refunds rather than replacement coupons. Column | Article

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.